Denagard is applied across domains where additional symptomatic support is needed for specific bacterial and Mycoplasmal infections in livestock. It is commonly used across conditions presenting with acute episodes, including Swine Dysentery, Ileitis (Porcine Proliferative Enteropathy), and various respiratory and locomotor infections in swine and poultry.

---

Symptom Management and Functional Support

The medication is relevant in contexts marked by increased discomfort or tension related to the gastrointestinal tract. It helps address symptom clusters that may become intense or disruptive, including acute diarrhea and associated intestinal distress, persistent coughing, respiratory distress, and lameness from joint infections.

“It supports the management of distressing manifestations and assists with maintaining functional stability.”

A key therapeutic benefit is commonly used to help with stability in the affected groups. By managing the disruptive symptom manifestations, it may assist with supporting functional parameters, such as growth rate and feed efficiency during symptomatic periods.

---

Quick Fact: Relief for Enteric & Respiratory Strain
Used for managing symptoms of both acute diarrhea and persistent pulmonary dysfunction in groups experiencing temporary physiological imbalance.

Regulatory References

1. European Commission veterinary product register

Eligibility Map: Who can and cannot use Denagard — Official Regulatory Information

This medicine is a veterinary product and its eligibility profile is strictly defined by regulatory documents based on species and concurrent medication.

---

Eligibility Scope

Classification	Target Populations/Status
Populations for whom use is Allowed	Swine (pigs), Chickens, and Turkeys of all age stages (e.g., poults, piglets, breeders).
Populations for whom use is Contraindicated	Humans (Not for use in humans). Animals with known Hypersensitivity to Tiamulin hydrogen fumarate.

---

Key Regulatory Restrictions

Restriction Type	Official Requirement
Absolute Contraindication	Animals must not receive Denagard if they are simultaneously receiving, or have received within the past seven days, any feed containing polyether ionophores (e.g., monensin, salinomycin, narasin). This prohibition is mandatory to prevent severe adverse reactions.
Pregnancy/Lactation Status	EU/UK Labeling: Permitted for use in pregnant and lactating pigs. US FDA Labeling: The effects on swine reproductive performance, pregnancy, and lactation are officially stated as not determined.

---

The official eligibility profile is fundamentally structured by species specificity and a critical drug-incompatibility constraint. Regulatory documents strictly define eligibility based on the target animal populations (swine and poultry) and impose an absolute non-eligibility rule when specific other medications are present.

Interactions with other Medicines and Products

The official interaction profile for Denagard (Tiamulin hydrogen fumarate) is defined by specific restrictions and mandatory prohibitions documented in regulatory labels concerning co-administration with other veterinary medicinal products.

---

Official Regulatory Interaction Constraints

Category	Official Regulatory Description
Contraindicated Drug Class	Polyether Ionophores (e.g., monensin, narasin, salinomycin, lasalocid, semduramicin)
Pharmacodynamic Interaction	Beta-lactam antibiotics (may lessen antibacterial activity)
Exposure Risk Modification	Polyether Ionophores (co-administration increases the risk of ionophore toxicity)
Mandatory Timing Rule	Ionophores must not be received during or for at least seven days before or after treatment with Tiamulin

---

The primary constraint is the formally contraindicated co-administration of Tiamulin with the Polyether Ionophore class. This prohibition is necessary because the official interaction is described as resulting in adverse reactions, including the risk of severe growth depression or death, which is attributed to an officially documented interference with the ionophores' metabolism.

This high-level severity classification requires a mandatory seven-day separation window between the administration of Tiamulin and incompatible ionophore-containing products. Furthermore, regulatory documents specify that Tiamulin may cause pharmacodynamic antagonism, thereby potentially lessening the antibacterial activity of beta-lactam antibiotics.

The Mechanism of Tiamulin Hydrogen Fumarate

The action of Tiamulin hydrogen fumarate (Denagard) is anchored in its molecular interaction with the fundamental machinery of susceptible microbial cells. The drug functions as an inhibitor by binding specifically to the 50S ribosomal subunit of the bacterial ribosome . This interaction occurs at or near the peptidyl transferase center (PTC). The binding physically blocks the enzyme's function, preventing the formation of peptide bonds and arresting the elongation of the polypeptide chain. This targeted molecular interference halts the synthesis of proteins essential for microbial replication and function. The resulting cellular consequence is bacteriostasis, which is the cessation of growth and proliferation of the microbial population within the host. This mechanism is highly selective, discriminating against the host's ribosomal structures. The physiological result is the suppression of the pathogen load in affected tissues. The mechanism is constrained by microbial acquired resistance, where ribosomal modification can reduce the drug's binding affinity, limiting the functional blockade.

How to Use Denagard: Administration Guidelines

Denagard (Tiamulin hydrogen fumarate) is administered exclusively via the oral route in livestock, using either a Liquid Concentrate prepared as a medicated drinking water solution or a Medicated Feed Premix.

Target Species & Form	Standard Daily Dosing (Active Substance)	Required Duration
Swine (Oral Solution)	3.5 mg/lb or 8.8 mg/kg body weight daily	5 consecutive days
Swine (Feed Premix)	5 to 10 mg/kg body weight daily	7 to 14 consecutive days
Poultry (Water/Feed)	25 to 40 mg/kg body weight daily	3 to 5 consecutive days

Procedural Instructions and Constraints

There are several key steps for proper administration:

• Dose Calculation: The concentration of Tiamulin hydrogen fumarate in the water or feed must be adjusted to compensate for variations in body weight and water/feed consumption within the group, ensuring the specified mg/kg or mg/lb dose is accurately delivered daily.
• Preparation: If using the Liquid Concentrate, fresh medicated water must be prepared every day of the treatment period, and the concentrate should not be used undiluted.
• Intake: The medicated water or feed should be the sole source of fluid or nourishment for the entire prescribed duration.
• Restriction: The medicine must not be administered to animals receiving polyether ionophores (such as monensin, narasin, or salinomycin) in their feed, including for a minimum of seven days before or after treatment.

This protocol standardizes how the required daily dose is delivered and specifies the total course length for effective usage.

Research Evidence / Overview of Studies for Denagard

Evidence for Use in Swine Enteric Infections (Dysentery and Ileitis)

Research reviewed for the authorized use of Denagard focused on two primary indications related to gastrointestinal conditions: Swine Dysentery and Porcine Proliferative Enteropathy (Ileitis). Studies conducted for these purposes often involved Randomized Block Design Field Trials and Controlled Laboratory Efficacy Trials that examined the product's application in settings of two key gastrointestinal conditions. Researchers monitored key outcomes related to physical discomfort and systemic or functional imbalance, including rates of mortality, clinical sign occurrence, and functional parameters like weight gain and feed conversion.

The regulatory evidence for these two core indications includes data from pivotal studies, which regulators describe as well-controlled research. However, few data are available for extended, long-term control strategies beyond the typical trial observation periods. Research gaps have also been noted regarding efficacy confirmation against certain related, newly identified Brachyspira species that may be involved in enteric infections.

---

Evidence for Use in Respiratory Conditions in Swine and Poultry

Research has also explored Denagard in the context of bacterial and Mycoplasmal respiratory conditions in both swine and poultry. The evidence in this domain generally relies on Controlled Clinical Trials and Pharmacokinetic/Pharmacodynamic (PK/PD) studies. PK/PD research examined the achievement of drug concentration in target respiratory tissues, which provides data on the achievable drug concentration in the site of infection.

Studies for these uses examined outcomes such as the measurement of changes in clinical respiratory signs, rates of mortality, and PK/PD parameters. The evidence base for these uses is characterized by studies relying partly on PK/PD modeling to evaluate concentration attainment. The available studies are typically short-term, limited to the five-day treatment period, meaning there is limited information regarding long-term control of disease manifestations or recurrence patterns following the initial study period.

Key Studies & References

1. Community Register of Veterinary Medicinal Products - Denagard 100 mg/ml solution for use in drinking water
2. Randomized Clinical Trials Assessing Tiamulin Efficacy Against Swine Dysentery (Brachyspira hyodysenteriae) in Swine
3. Efficacy of Tiamulin in Experimental Challenge Models of Porcine Proliferative Enteropathy (Lawsonia intracellularis)
4. Studies on Tiamulin Efficacy and Pharmacokinetics in Mycoplasmal Infections (M. gallisepticum) in Poultry

Common questions about Denagard (FAQ)

Q: Is Denagard an antibiotic?

Official regulatory documents describe the active ingredient, Tiamulin hydrogen fumarate, as an effective semi-synthetic diterpene antibiotic. It belongs to the unique Pleuromutilin group of anti-infective agents.

Q: Does it cause weight gain/loss?

According to the official product indications for medicated feed, a low-dose regimen of Denagard is used to achieve an increased rate of weight gain and improved feed efficiency in swine. This is listed as an approved indication for the product.

Q: How long does it stay in the system of the treated animal?

The primary regulatory concern regarding clearance is ensuring food safety. Official product information specifies a required withdrawal period (e.g., 3 or 7 days in swine) that must be observed between the last treatment and the time the animal can be processed for food, intended to ensure that tissue residues are below established tolerances.

Q: How long does it take for the medicine to start acting?

Studies and official information indicate that the active ingredient is rapidly absorbed into the animal's system. Tiamulin can be found in the blood of the target animal within approximately 30 minutes after initial administration. The rapid absorption allows the medication to reach the circulatory system of the treated animal shortly after administration.

Q: Can this product be bought without a prescription?

The marketing status of Denagard varies by formulation and regulatory region. Some formulations have been designated with an 'Over-the-counter marketing status,' while other medicated feed premixes may be restricted to use only under a Veterinary Feed Directive (VFD) from a licensed veterinarian.

Q: What if an animal accidentally receives too much?

In the target animals, administering an excessive amount of the product has sometimes resulted in signs of overdose. These may include transitory salivation, vomiting, and an apparent calming effect. Signs of overdose are typically managed with professional oversight.

Q: What are the signs of a non-allergic reaction?

Adverse reactions reported in the target animal outside of severe allergic responses include transitory salivation, vomiting, and, in rare instances, redness of the skin, typically observed over the ham and underline of the animal. These signs are typically self-limiting and are usually addressed with professional monitoring.

Q: Is this product a steroid?

No. According to official regulatory documents, Tiamulin hydrogen fumarate, the active ingredient in Denagard, is classified as a semi-synthetic diterpene antibiotic. It belongs to the unique Pleuromutilin group of anti-infective agents.

Q: Is Denagard safe for children?

Regulatory labels state that Denagard is a veterinary product and is explicitly not for human use. Safety warnings emphasize the importance of keeping the product out of the reach of children.

Q: Can a 2-year-old child use it?

Denagard is a veterinary product and is not intended for human use. Safety warnings emphasize that the product must be stored and maintained out of the reach of children.

Q: Is it safe for the elderly?

Official regulatory labels confirm that this is a veterinary product and is Not for Human Use. Safety information is strictly limited to the product's use in the target animals (swine and poultry).

Q: Can I drive or operate machinery while taking this?

Regulatory documents explicitly state that this product is a veterinary medicine and is Not for Human Use. Therefore, there are no official instructions regarding its effects on a person’s ability to drive or operate machinery.

Q: Does it make you sleepy?

Official regulatory documents report that in cases of overdose in the target animals, an apparent calming effect has been observed. This is noted in safety summaries as a potential consequence of excessive administration, rather than a typical effect at therapeutic doses.

Q: Can the treated animal receive this with other antibiotics?

The official interaction profile includes a severe warning that Denagard must not be administered in conjunction with feeds or water containing any polyether ionophores (such as monensin or salinomycin). This specific combination has been associated with severe adverse reactions in the target animal.

Q: Can the treated animal receive this with food or on an empty stomach?

Administration instructions state that the medicated drinking water or medicated feed must be the sole source of nourishment or fluid for the target animals throughout the entire treatment period. This is done to promote consistent daily delivery of the intended dose.

Q: Is it safe for a dog?

Official product labeling clearly restricts the use of Denagard to the approved target species, which are swine and poultry. The product label states it is 'Not for use in feeds for animals other than swine' and is explicitly 'Not for Human Use.'

How to Store and Dispose of Denagard (Tiamulin Hydrogen Fumarate)

The storage and disposal of Denagard must adhere to specific regulatory requirements to maintain product stability and safety.

Storage Requirements

Formulation	Required Temperature	Protection Constraints
Liquid Concentrate	Controlled room temperature (59 F–77 F)	Protect from direct sunlight
Coated Premix	At or below 77 F	Protect from light and moisture

The labeling mandates that Denagard, in any formulation, must be stored out of reach of children. The required temperature and protection constraints are essential for maintaining the stability of the medicine.

Disposal Instructions

Disposal of unused or expired Denagard and its container must be performed in accordance with local, regional, national, or international regulations for pharmaceutical waste. To ensure environmental protection, the product should not be disposed of in wastewater or standard household waste unless explicitly authorized by regulatory bodies.